(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement for its drug Rinvoq for the treatment of adults with moderately to severely ...

AbbVie's strong results, pipeline wins, and Rinvoq exclusivity boost its outlook. Read the latest analysis on ABBV stock here.

Skyrizi, Rinvoq sales expected to surpass $31 billion by 2027 Humira sales decline 49% due to cheaper biosimilar competitors AbbVie earns $2.16 per share in Q4, beats estimates Jan 31 (Reuters) - ...

AbbVie has struck a deal with generic drugmakers aimed at extending patent protection for its blockbuster autoimmune drug Rinvoq by more than a decade. AbbVie on Thursday said it has settled ...

Please provide your email address to receive an email when new articles are posted on . Upadacitinib is an oral JAK inhibitor under investigation for multiple dermatologic indications. The drug ...

As in any month, September was eventful for AbbVie. In addition to news about its usual activities, it also scored big with ...

AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...